07:42 AM EDT, 06/07/2024 (MT Newswires) -- Geron ( GERN ) shares were up 28% premarket Friday after the company said it received US Food and Drug Administration approval for its drug Rytelo as a treatment for adult patients with lower-risk myelodysplastic syndrome, a type of leukemia.

Braze (BRZE) shares were 15% higher after the company reported a narrower fiscal Q1 non-GAAP net loss and higher revenue in addition to raising its fiscal 2025 outlook.

Four Seasons Education ( FEDU ) stock was up 14%, rebounding from Thursday's fall.

VYNE Therapeutics ( VYNE ) shares were 13% higher following a 1.7% gain in the previous session.

Price: 4.9900, Change: +1.10, Percent Change: +28.28